Real-world study of Nerivio Migra in migraine published in Pain Medicine.- Theranica

Theranica announced the publication of a new real-world post-marketing surveillance study in Pain Medicine that demonstrates the safety, efficacy and consistency of the company's Nerivio therapeutic wearable device. The study evaluated two cohorts of patients with episodic and chronic migraine. One group utilized in-person visits with headache specialists, while the other cohort included patients who were managed through a single-specialty or multi-specialty online telemedicine platform. Observed patients used Theranica's Nerivio without complementary treatments. The headache specialist group consisted of 1,339 evaluated patients, many of whom were chronic migraine patients, and 2,875 treatments. 58.9% of these patients experienced pain relief, and 20% experienced pain freedom at 2 hours in at least half of their treated attacks. Additionally, 52.9% and 25.8% reported an improvement or a complete return to normal functioning, respectively, 2 hours after starting the treatment. The telemedicine cohort consisted of 45 evaluated patients and 78 treatments. 74.2% of the patients in this group experienced pain relief and 35.6% experienced pain freedom at 2 hours in at least half of their treated attacks. Additionally, 66.7% and 51.3% reported an improvement or a return to normal functioning, respectively. In terms of safety, only 0.5% of all patients experienced any kind of adverse event, and all adverse events were categorized as mild, non-systemic, and resolved within less than 24 hours. See: "Real-world Experience with Remote Electrical Neuromodulation in the Acute Treatment of Migraine" Stewart J Tepper et al. Pain Medicine, pnaa299, https://doi.org/10.1093/pm/pnaa299 Published: 16 September 2020